Leap Therapeutics (NASDAQ:LPTX) is a clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology and targeted therapies for the treatment of solid tumors. The company’s research efforts center on leveraging both innate and adaptive immune mechanisms as well as tumor‐activated antibody platforms to enhance antitumor efficacy while minimizing off‐target effects. Leap’s portfolio includes proprietary oligonucleotide-based immune modulators alongside protease-activated antibodies designed to engage tumor cells selectively within the tumor microenvironment.
The lead program in Leap’s pipeline is a Toll-like receptor 9 (TLR9) agonist, which is designed to stimulate the body’s innate immune response against cancer. This candidate has advanced into clinical trials, where it is being evaluated as both a monotherapy and in combination with immune checkpoint inhibitors. In parallel, Leap is advancing a novel probody therapy targeting the PD-L1 immune checkpoint, engineered to remain inactive until it encounters tumor-associated proteases. Preclinical results have demonstrated this approach may improve the safety and tolerability profile compared to conventional checkpoint blockade.
Headquartered in Westlake Village, California, with research operations in Shanghai, China, Leap Therapeutics maintains a global footprint to support both early-stage development and international clinical collaborations. The company has established strategic partnerships with contract research organizations and academic centers to accelerate pipeline progress and to explore combination strategies with other immunotherapies and targeted agents. Leap’s multidisciplinary team integrates expertise in oncology, immunology, biochemistry and translational medicine to drive its clinical development plans.
Leap Therapeutics was founded in 2014 and is led by a management team with extensive experience in drug development, regulatory affairs and commercial strategy. The company’s board and scientific advisory group include seasoned biotech executives and renowned academic researchers in oncology. Together, they guide Leap’s mission to bring innovative, tumor-selective treatments to patients with high unmet medical needs across North America, Europe and Asia.
